List view / Grid view
22 July 2015 | By Victoria White
Biogen has announced new results from an interim analysis of the Phase 1b PRIME study of aducanumab in patients with prodromal or mild Alzheimer’s disease...
22 July 2015 | By Victoria White
Lilly has announced results suggesting that solanezumab slows the progression of Alzheimer's in patients with mild disease...
8 July 2015 | By Victoria White
AXON Neuronscience's vaccine intended to be a disease modifying drug for Alzheimer’s disease patients has passed a Phase 1 safety trial...
6 July 2015 | By Victoria White
Over three quarters of UK GPs think their patients with dementia rely on family as they do not get enough help from health and social care services...
2 July 2015 | By Victoria White
Evotec and Roche have provided an update on the initial results of the Phase IIb trial with Sembragiline for the treatment of Alzheimer's disease...
24 June 2015 | By Victoria White
A Phase 2/3 clinical study of ELND005 in agitation and aggression in patients with Alzheimer's disease (AD) did not meet its primary efficacy endpoint...
17 June 2015 | By Victoria White
Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, has announced the positive outcome of its Phase 1a study with HTL9936...
7 May 2015 | By Victoria White
The global market for Alzheimer’s disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023...
23 April 2015 | By Victoria White
Napp and a group of experts in the fields of pain management and dementia care have launched a training resource to help carers identify signs of pain...
24 March 2015 | By Victoria White
Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases...
23 March 2015 | By Victoria White
Biogen Idec has announced data from the Phase 1b study of aducanumab, in which the drug demonstrated positive results in patients with prodromal or mild AD...
24 February 2015 | By GBI Research
While drug candidates for Alzheimer’s Disease fail at a much higher rate than the pharmaceutical industry average, the total number of active drugs in the AD treatment pipeline is relatively large at 583, implying a high level of commercial interest, says business intelligence provider GBI Research...
31 October 2014 | By Actinogen Ltd
Actinogen Ltd, an Australian biotechnology company, has acquired Edinburgh BioQuarter spin-out, Corticrine Ltd in a deal facilitated and introduced by Professor Alan Boyd of Boyds...
13 October 2014 | By Probiodrug AG
Probiodrug AG announces the launch of its Initial Public Offering and listing on Euronext Amsterdam...
23 September 2014 | By GlobalData
Eli Lilly’s recent partnership with AstraZeneca to develop oral beta-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer’s Disease (AD) is a positive step forward for this challenging treatment market, says an analyst with research and consulting firm GlobalData...
